NurExone Biologic Finalist in Falling Walls Venture 2025 Global Platform Showcasing The World's Most Promising Science-Based Start-Ups

Core Points - NurExone Biologic Inc. has been named a finalist in Falling Walls Venture 2025, showcasing its potential in the field of science-based start-ups [1][2] - The company's lead product, ExoPTEN, aims to address central nervous system injuries, which impose significant personal and economic burdens [2][4] - NurExone will present its exosome-based regenerative therapy platform at the Falling Walls Science Summit in Berlin from November 6-9, 2025 [2][3] Company Overview - NurExone is a biotech company listed on TSX Venture Exchange, OTCQB, and Frankfurt, focusing on developing regenerative exosome-based therapies for central nervous system injuries [4] - ExoPTEN has shown promising preclinical data for treating acute spinal cord and optic nerve injuries, both of which represent multi-billion-dollar markets [4][10] - The company has received Orphan Drug Designation, facilitating its roadmap towards clinical trials in the U.S. and Europe [4] Event Participation - As a finalist, NurExone will have access to exclusive networking events, connecting with investors, strategic partners, and global thought leaders [3] - The Falling Walls Science Summit serves as a platform for finalists to pitch their innovations, with one being awarded the title 'Science Breakthrough of the Year' [3]